Quantcast

Latest Cebix Incorporated Stories

2011-06-24 16:00:00

LA JOLLA, Calif., June 24, 2011 /PRNewswire/ -- Cebix Incorporated announced today that preclinical data for its long-acting form of C-peptide, Ersatta(TM) (CBX129801), demonstrated a half-life of three days as compared to one hour for native C-peptide.

2011-06-16 07:00:00

LA JOLLA, Calif., June 16, 2011 /PRNewswire/ -- Cebix Incorporated announced today it is advancing the development of modified C-peptide for the treatment of complications of diabetes.